Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating Costs and Expenses:
General and administrative	$ 2,426	$ 1,713
Research and development	8,155	6,494
Total Operating Costs and Expenses	10,581	8,207
Loss from Operations	(10,581)	(8,207)
Other Income (Expense):
Change in fair value of warrant liability	(498)	(4,152)
Interest income	1	1
Total Other Income (Expense)	(497)	(4,151)
Net Loss	(11,078)	(12,358)
Net Loss Attributable to Non-controlling Interest	(233)	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (10,845)	$ (12,358)
Net Loss Per Share - Basic and Dilutive (in dollars per share)	$ (0.12)	$ (0.17)
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)	90,826,752	72,673,959